Ascendis Pharma (ASND) Reports Q2 Loss of EUR0.55/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results
August 29, 2018 4:01 PM EDT- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon technology in a new therapeutic area -
- Conference Call Today at 4:30 p.m. Eastern Time -
COPENHAGEN, Denmark, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the quarter ended June 30, 2018.
We continue to execute on our... More
